Nasdaq 100 Stocks SEC Filings — May 29, 2026

29-05-2026

Community West Bancshares held its Annual Meeting on May 27, 2026, with 72.23% of outstanding shares represented. All 13 director nominees were elected, and shareholders ratified the appointment of Baker Tilly LLP as independent auditor with overwhelming support (99.9% of votes cast). However, the non-binding advisory resolution on executive compensation received notable opposition, with 876,079 votes against (5.4% of votes cast) and 60,855 abstentions, indicating some shareholder dissent on pay practices.

• · Daniel J. Doyle received the lowest support among director nominees with 12,913,074 votes for and 3,292,881 votes withheld (20.3% withheld).
• · Kirk B. Stovesand also had significant withheld votes: 123,883 against 13,053,991 for (0.9% withheld).
• · All director elections had 3,372,885 broker non-votes, representing about 17.2% of shares represented.
• · The advisory compensation resolution had 15,269,021 votes for, 876,079 against, and 60,855 abstentions, plus 3,372,885 broker non-votes.
• · The auditor ratification had no broker non-votes, with 19,556,109 for, 12,393 against, and 10,338 abstentions.

29-05-2026

Faraday Future Intelligent Electric Inc. (FFAI) announced a strategic partnership with Sequoia Education Center, a leading K-12 education group in North America, and signed a sales contract for 23 FF EAI robots, its largest robot order to date. The company also delivered a Master humanoid robot to a medical institution in Los Angeles, marking its first healthcare use case. At the annual stockholders' meeting on May 22, 2026, all proposals received roughly 80% approval support. However, the filing also highlights ongoing risks including the company's ability to continue as a going concern, lack of sufficient share capital, and potential Nasdaq delisting if the stock price falls to $0.10 or less for 10 consecutive trading days.

• · The company has delivered a Master humanoid robot to a medical institution in Los Angeles, its first healthcare use case.
• · FF's collaboration with RobotShop is progressing smoothly, and several major North American e-commerce platforms have expressed interest in partnering on robotics sales.
• · The EAI Brain and Skills ecosystem has developed dozens of Skills covering education, security, reception, guided tours, and companion services.
• · The developer platform includes six major tools; two (BrainBlocks and EAI Soul) are already completed, with the remaining tools rolling out later in May 2026.
• · Decentralized real-world robot data collection is expected to be completed in June 2026.
• · The company faces risks including potential Nasdaq delisting if the stock price falls to $0.10 or less for 10 consecutive trading days, and the need for substantial additional funding to execute its FX strategy.

29-05-2026

Meta Platforms, Inc. held its 2026 Annual Meeting on May 27, 2026, where shareholders elected all twelve director nominees, including Mark Zuckerberg and others, and ratified Ernst & Young LLP as independent auditor for FY 2026. However, all ten shareholder proposals—covering topics such as AI data usage oversight, executive pay, dual class capital structure, human rights, antisemitism, climate change, child safety, generative AI chatbots, and H-1B visa risks—were overwhelmingly defeated. Quorum was achieved with 92.19% of combined voting power represented.

• · Record date for voting was April 1, 2026.
• · Broker non-votes totaled 212,856,564 on each director election and each shareholder proposal.
• · All director nominees received over 4 billion votes 'for'; John Elkann had the highest 'withheld' votes at 858,647,251.
• · The shareholder proposal on H-1B visa risks received the fewest 'for' votes: only 11,628,532 (0.2% of votes cast).

29-05-2026

Apple Hospitality REIT, Inc. filed an 8-K on May 29, 2026, disclosing an updated investor presentation containing operating statistics for April and May 2026. The presentation is furnished as Exhibit 99.1 and is intended for use at upcoming conferences and meetings. The filing is a Regulation FD disclosure and does not contain detailed financial results or period-over-period comparisons.

• · The investor presentation was made available on the company's website on May 29, 2026.
• · The presentation includes operating statistics for April and May 2026.
• · The filing is furnished under Items 7.01 and 9.01 of Form 8-K and is not deemed filed for Exchange Act purposes.

29-05-2026

CCC Intelligent Solutions Holdings Inc. filed an 8-K/A to disclose compensation arrangements for Rodney Christo, who was appointed Interim Chief Financial Officer following Brian Herb's resignation. Christo's base salary increases to $425,000 per year for a transition period, and he is eligible for a one-time transition cash bonus between $125,000 and $200,000, contingent on the length of the transition and successful onboarding of a successor CFO. The filing does not include any financial performance data, so no period-over-period comparisons are available.

• · The transition period begins on May 25, 2026 and continues until a successor CFO is appointed and onboarded.
• · The transition bonus is payable in a lump sum on the first payroll date after the earlier of the end of the transition period or December 31, 2026.
• · The transition bonus is forfeited if Christo's employment is terminated by the company for cause or by him without good reason before the payment date.
• · Christo will continue to serve as Chief Accounting Officer while serving as Interim CFO.

29-05-2026

Aditxt, Inc. (ADTX) received a Nasdaq Staff letter on May 27, 2026, notifying it of non-compliance with the minimum stockholders' equity requirement of $2.5 million, reporting negative equity of $(35,174,386) as of March 31, 2026. This adds to a prior delisting determination based on the minimum bid price rule, with a hearing scheduled for June 11, 2026. The company also acknowledges it is currently not in compliance with the minimum Market Value of Publicly Held Shares requirement of $1,000,000, though no formal notification has been received yet.

• · The company's stockholders' equity was $(35,174,386) as of March 31, 2026, far below the $2.5 million minimum.
• · The company also fails the alternative listing standards: market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recent fiscal year or two of the last three.
• · A prior delisting determination was received on May 6, 2026, for failure to comply with the minimum bid price requirement and ineligibility for a compliance period due to reverse stock split history.
• · The hearing before the Nasdaq Hearings Panel is scheduled for June 11, 2026.
• · The company is also currently not in compliance with the minimum Market Value of Publicly Held Shares of $1,000,000, though no formal notification has been received yet.
• · The Panel has broad discretion to delist the company based on factors including reverse stock split history, financial condition, going concern, capital structure, and capital-raising activities.

29-05-2026

Immunic, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 annual meeting of stockholders, scheduled for June 29, 2026. The filing details the election of three Class III directors (Thorvald Nagel, Dr. Richard Rudick, and Michael Bonney) and notes that CEO Dr. Daniel Vitt resigned effective June 1, 2026, but will remain on the board to oversee scientific strategy. The board consists of ten members, eight of whom are independent, and the company has adopted a staggered board structure with three-year terms.

• · The annual meeting is scheduled for June 29, 2026.
• · Stockholder proposals for the 2027 annual meeting must be submitted according to deadlines described in the proxy statement.
• · The company uses 'householding' to deliver a single copy of proxy materials to stockholders sharing an address.
• · A list of stockholders entitled to vote will be available at the meeting and from the corporate secretary for ten days prior.
• · Dr. Daniel Vitt resigned as CEO effective June 1, 2026, but remains on the board for scientific strategy.
• · Dr. Duane Nash served as Chairman from April 2019 to December 2025 and as Executive Chairman from April 2020 to December 2025.
• · Michael Bonney previously led Cubist Pharmaceuticals, which was acquired by Merck for $9.5 billion.
• · Thorvald Nagel joined the board in February 2026 and is an analyst at BVF.
• · Dr. Jon Congleton joined the board in 2026 as a continuing Class II director.

29-05-2026

Entravision Communications Corporation (EVC) held its 2026 annual meeting on May 28, 2026, where stockholders elected seven directors, ratified Deloitte & Touche as auditor for FY2026, approved non-binding executive compensation, and approved an amendment to the 2004 Equity Incentive Plan increasing shares authorized by 6,000,000. While the executive compensation advisory vote passed with about 83.5% of votes cast in favor, the equity plan amendment was approved by a narrower margin with only 70.1% of votes cast in favor; director Fehmi Zeko received a relatively high 17.1% withhold vote, indicating some investor dissent.

• · The equity plan amendment was approved with 43,546,376 FOR vs 18,546,733 AGAINST (70.1% in favor of votes cast, excluding broker non-votes).
• · Executive compensation advisory vote: 51,920,969 FOR, 10,171,084 AGAINST, 23,085 abstentions (83.6% in favor of votes cast).
• · Ratification of Deloitte & Touche passed overwhelmingly: 71,402,716 FOR, 158,992 AGAINST, 21,396 abstentions.
• · Director Fehmi Zeko received the highest withhold vote tally among directors: 10,654,102 withheld (17.1% of votes cast, excluding broker non-votes).
• · All other directors received over 97% support among votes cast excluding broker non-votes.

29-05-2026

TMC the metals Co Inc. held its Annual Meeting on May 28, 2026, with 49.3% of eligible shares represented. Shareholders approved setting the board at ten directors, elected all director nominees, ratified Ernst & Young as auditor for 2026, and approved say-on-pay on a non-binding basis. However, the say-on-frequency vote resulted in a two-year frequency, meaning the next advisory vote will be in 2028, which may not align with investor preferences for annual votes.

• · The say-on-frequency vote received 184,853,982 votes for 2 years, 26,301,819 for 1 year, and 1,066,681 for 3 years, with 1,153,565 abstentions.
• · The next advisory say-on-pay vote will be held at the 2028 annual meeting.
• · There were no broker non-votes on any proposals.

29-05-2026

CoStar Group announced a definitive agreement to acquire Zonda, a leader in new home data, analytics, and online marketplaces, for $800 million in cash. The acquisition is expected to be accretive to adjusted EPS in the first full year of ownership and close in the second half of 2026, subject to regulatory approvals. While Zonda boasts strong subscription-based revenue with 104% net customer retention and serves over 3,000 customers, the deal carries integration risks and requires regulatory clearance.

• · Zonda's platform includes Envision visualization and digital merchandising capabilities that will be paired with Matterport's spatial technology.
• · The acquisition is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.
• · BofA Securities is serving as financial advisor and Latham & Watkins LLP as legal advisor to CoStar Group.
• · CoStar Group's websites attracted 131 million average monthly unique visitors in Q1 2026.

29-05-2026

Axiom Intelligence Acquisition Corp 1 (SPAC) has entered into a definitive Business Combination Agreement dated May 25, 2026, to acquire Terra Quantum AG, a Swiss quantum technology company, through a two-step merger structure. The transaction involves the formation of a Swiss public holding company (PubCo) and a merger of SPAC with a subsidiary, followed by the acquisition merger of Swiss HoldCo into PubCo, with the combined entity expected to be publicly traded. The agreement includes sponsor and shareholder support agreements, lock-up provisions, and an earnout mechanism, but no specific financial terms (e.g., valuation, PIPE size, or trust account balance) are disclosed in this excerpt.

• · The SPAC Board unanimously approved the transaction and deemed it in the best interests of SPAC.
• · Sponsor Support Agreement requires Sponsor to vote in favor, not redeem shares, and not transfer SPAC securities.
• · Shareholder Support Agreements include lock-up provisions for certain PubCo Ordinary Shares post-closing.
• · The transaction is structured to qualify as a tax-free reorganization under Section 368(a)(1)(F) of the U.S. Internal Revenue Code.
• · A Registration Rights Agreement will be entered into at closing among PubCo, Sponsor, SPAC, and certain Swiss HoldCo shareholders.
• · The agreement includes a trust account waiver by the Company and its shareholders.

29-05-2026

Mullaney, Keating & Wright, Inc. reported its 13F-HR filing for the period ending December 31, 2024, disclosing a total portfolio value of approximately $148.1 million across 60 equity positions. The filing shows a diversified portfolio with significant allocations to iShares ETFs (including Russell 1000, Mid-Cap, and Value ETFs), Sherwin-Williams, and Vanguard inflation-protected securities. No prior-period comparison data is available in this filing, so period-over-period changes cannot be assessed.

• · Top holdings by value include iShares Russell 1000 ETF ($16.9M), iShares Russell Mid-Cap ETF ($8.2M), iShares Russell 2000 Value ETF ($4.7M), iShares Russell Mid-Cap Value ETF ($5.7M), and Sherwin-Williams ($5.5M).
• · The firm holds a significant position in Vanguard Short-Term Inflation-Protected Securities Index Fund ($6.0M).
• · Apple Inc. is the largest single-stock holding by value ($53.6M), followed by Microsoft ($1.1M) and Exxon Mobil ($0.7M).
• · The filing includes multiple Dimensional ETF Trust funds with combined value exceeding $2.5M.
• · No options or convertible securities are reported; all positions are common stock or ETF shares.

29-05-2026

Replimune Group issued a press release on May 29, 2026, announcing that following collaborative communications with the FDA, it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. The resubmission marks a regulatory step forward after prior discussions with the agency.

• · The resubmission follows collaborative communications with the FDA.
• · The BLA is for RP1 in combination with nivolumab for the treatment of advanced melanoma.
• · The news release was furnished as Exhibit 99.1 to the Form 8-K.
• · The filing is under Item 7.01 (Regulation FD Disclosure) and is not deemed filed for Section 18 purposes.
• · The report was signed by Sushil Patel, CEO.

29-05-2026

United Community Banks Inc. (UCB) is providing a weekly update on its pending merger with Peach State Bancshares, Inc., announcing key milestone dates including a legal close in Q3 2026 (subject to regulatory approval) and a conversion scheduled for February 12–16, 2027. The filing introduces Rich Bradshaw, President & CBO, who will visit the Peach State team, and highlights United's community-focused initiatives. No financial figures or performance metrics are disclosed in this communication.

• · Legal close of the merger is targeted for Q3 2026, subject to regulatory approval.
• · Conversion is scheduled for February 12–16, 2027.
• · Rich Bradshaw oversees more than 200 branches across United's six-state footprint.
• · United filed a registration statement on Form S-4 on May 28, 2026, which includes a proxy statement for Peach State shareholders.
• · The SEC has not yet declared the registration statement effective.
• · United's 2026 annual meeting proxy statement was filed on April 1, 2026.

29-05-2026

First Community Corporation filed an 8-K on May 29, 2026, furnishing an investor presentation for the 2026 Performance Trust Capital Connect Conference on June 1-2, 2026. The presentation highlights the January 2026 acquisition of Signature Bank of Georgia, strong loan growth of 13.1% annualized in Q1 2026 (excluding the acquisition), and eight consecutive quarters of net interest margin expansion. However, non-interest bearing deposits declined to 27% of total deposits from 29% a year earlier, and the investment portfolio yield remained low at 3.32%.

• · The company has paid dividends for 97 consecutive quarters with a current yield of 2.11% based on a May 26, 2026 closing price of $30.38.
• · Loan principal cash flows (excluding prepayments) for Q2 2026 are $92.6 million at a weighted average rate of 6.09%; for Q2–Q4 2026 total $214.8 million at 6.02%.
• · Investment portfolio principal cash flows for Q2–Q4 2026 are $44.4 million at a weighted average rate of 3.94%.
• · The investment portfolio has an average life of 5.2 years and effective duration of 3.3 years.
• · Non-interest bearing deposits remained flat at 27% of total deposits from Q4 2025 to Q1 2026, but declined from 29% in Q4 2023.
• · Total deposits grew to $2,148.1 million at Q1 2026, including $229.8 million from the Signature Bank acquisition.
• · The company's leverage ratio (bank) and total capital ratio (bank) are shown in the presentation but specific values are not provided in the text.
• · Tangible book value and tangible common equity data are presented in the slides but exact figures are not included in the extracted text.
• · The company received Preferred Lender Status from the SBA on April 10, 2026.
• · GGL loan portfolio size: $52.6 million in loans held-for-investment and $0.6 million in loans held-for-sale.
• · Core net income and EPS for Q1 2026 are shown in thousands on slide 48, but exact figures are not provided in the extracted text.

29-05-2026

ACADIA Pharmaceuticals held its 2026 Annual Meeting on May 29, 2026, where stockholders elected three Class I directors (James M. Daly, Edmund P. Harrigan, M.D., Adora Ndu, Pharm.D., J.D.) and approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 5,209,670. All management proposals, including the advisory vote on executive compensation and ratification of Ernst & Young as independent auditor, were approved with strong majority support.

• · All three Class I director nominees were elected; Edmund P. Harrigan received the lowest support (128,460,130 FOR vs 21,988,617 WITHHELD).
• · Advisory vote on executive compensation passed with 148,265,173 FOR and only 1,911,358 AGAINST.
• · Ernst & Young was ratified as independent auditor for FY2026 with 157,409,378 FOR (98% of votes cast excluding broker non-votes).
• · The 2024 Equity Incentive Plan amendment was approved to increase authorized shares by 5,209,670 shares.
• · The amendment allows issuance of shares under the Plan for equity-based compensation.